Investment Rating - The report maintains an "Increase" rating for the food and beverage industry, indicating a positive outlook for the sector [5]. Core Views - The liquor industry is strengthening its internal capabilities, with companies focusing on management, product, and channel improvements. The industry is currently at a low valuation and is expected to stabilize as sales pressure eases [2]. - In the beer and beverage sector, East Peak Beverage reported impressive mid-year results, while the industry continues to show high growth potential despite intense competition [3]. - The report highlights the ongoing transformation in product selection at Sam's Club, emphasizing operational efficiency through local supply chain adjustments [4]. Summary by Sections Liquor Industry - The liquor sector is in a phase of continuous improvement, with major companies like Guizhou Moutai and Shanxi Fenjiu enhancing their management and product offerings. The industry is currently experiencing a seasonal downturn, but valuations are low, suggesting potential for recovery [2]. Beer and Beverage Sector - The beer segment is advised to focus on high-growth products and structural performance, with companies like Yanjing Beer and Zhujiang Beer being highlighted. East Peak Beverage's revenue for the first half of 2025 reached 10.737 billion yuan, a year-on-year increase of 36.37% [3]. Food Sector - Sam's Club is undergoing a significant product selection transformation, with a shift towards national best-selling items to improve operational efficiency. The report notes that the low-temperature dairy market is performing better than the ambient temperature segment [4][7].

Summary of Alotose Sugar Conference Call Industry Overview - Alotose sugar is a low-calorie, low glycemic index (GI) natural sugar with potential applications in health products and diabetic foods, particularly in the beverage and solid food sectors [1][3] - The approval of Alotose sugar as a new food ingredient by the National Health Commission of China is expected to drive significant structural growth opportunities in the domestic food and beverage industry [3][12] Key Points and Arguments - Alotose sugar is the only sugar substitute that can undergo the Maillard reaction, providing unique advantages in baked goods, such as improved color and aroma, along with good moisture retention [1][5] - The domestic market is increasingly focused on Alotose sugar, especially among beverage manufacturers like milk tea and tea drink producers, who are actively preparing relevant formulations [1][7] - The anticipated market introduction of Alotose sugar products is expected within six months, with innovative brands and tea companies likely to lead the way [12][20] - The commercial challenges for Alotose sugar include high costs and supply capacity issues, with current prices around 20,000 to 21,000 yuan per ton due to supply shortages [13][19] Market Dynamics - The U.S. market has seen significant growth in Alotose sugar applications since its approval in 2011, with 60% of applications in solid foods, 30% in beverages, and 10% in health products [6] - In China, beverage manufacturers are expected to adopt Alotose sugar more rapidly than solid foods to meet consumer demands for health and taste [8][9] - The expected growth rate for Alotose sugar is projected to be close to 60% in 2025, primarily driven by export markets [21] Competitive Landscape - Baidong Chuangyuan is a leading supplier in the global Alotose sugar market, accounting for 25% to 30% of the global market share with a projected output of over 12,000 tons in 2025 [16][21] - Other competitors have not yet announced clear expansion plans, allowing Baidong Chuangyuan to maintain its market advantage for the foreseeable future [16][17] Future Outlook - The market for Alotose sugar is expected to see significant growth by 2026 or 2027, driven by increased production capacity and rising consumer demand for health-functional ingredients [14][22] - The competitive landscape is unlikely to see an oversupply similar to that of erythritol in the near term, as domestic demand for Alotose sugar is still developing [15] - Baidong Chuangyuan's performance is expected to continue improving, with projected profits of 350 million yuan in 2025, reflecting a year-on-year growth of over 40% [22][23] Regulatory and Approval Process - The approval process for domestic production of Alotose sugar is ongoing, with companies like Baidong and Baolinbao actively seeking production licenses [18] - The speed of local market regulatory approvals is increasing, but the key approval from the National Health Commission remains critical [18] Conclusion - Alotose sugar presents a promising investment opportunity in the health and wellness sector, with its unique properties and growing market acceptance. The challenges of cost and supply must be managed carefully to capitalize on the expected growth trajectory in both domestic and international markets.

Core Viewpoint - The company is undergoing a board restructuring to enhance governance and adapt to business development needs, with the fourth board consisting of 7 directors, including 4 non-independent and 3 independent directors [1][2]. Non-Independent Directors - The company has nominated three candidates for the fourth board of non-independent directors: Dou Baode, An Lianlian, and Cui Hongyu, with a term of three years starting from the approval date by the shareholders' meeting [1][2]. - The nomination was approved by the third board's nomination committee and is in compliance with relevant laws and regulations [1][2]. Independent Directors - Three candidates have been proposed for the fourth board of independent directors: Niu Qiang, Xing Zhiliang, and Su Lingqia, also with a term of three years starting from the shareholders' meeting approval [2][5]. - The independent director candidates have completed the required training and have been filed as per regulations, pending review by the Shanghai Stock Exchange [2][5]. Other Information - All nominated candidates meet the qualifications and independence requirements as per the Company Law and the company's articles of association, with no disqualifying conditions [2][5]. - The current board will continue to operate until the new board is approved by the shareholders' meeting, and the company expresses gratitude for the contributions of the current board members [3].

Core Points - The document outlines the management system for the shares held by directors and senior management of Shandong Bailong Chuangyuan Biotechnology Co., Ltd, emphasizing compliance with relevant laws and regulations [1][2][3] Group 1: General Provisions - The system aims to strengthen the management of shares held by directors and senior management, clarifying procedures based on the Company Law and Securities Law [1] - The system applies to shares held by directors, senior management, and their concerted actors [1] Group 2: Shareholding Change Rules and Information Disclosure - Directors and senior management must notify the board secretary in writing before buying or selling company shares, and the board secretary must verify the situation [2][3] - There are restrictions on the transfer of shares held by directors and senior management, including a one-year lock-up period post-listing and a six-month restriction after leaving the company [4][5] Group 3: Transfer Limitations and Conditions - Directors and senior management can only transfer up to 25% of their shares annually, with exceptions for certain circumstances [5][6] - New shares acquired under specific conditions are subject to different transfer rules, including a 25% limit for unrestricted shares in the year of acquisition [6][7] Group 4: Reporting and Disclosure Obligations - Any changes in shareholding must be reported within two trading days, including details of the change [8][9] - A reduction in shares due to divorce must also comply with the reporting rules [8] Group 5: Penalties and Responsibilities - Violations of the share trading rules may result in internal disciplinary actions or legal consequences, including the recovery of profits from short-term trading [11][12] - The board secretary is responsible for reporting violations to the board, stock exchange, and local regulatory authorities [11][12] Group 6: Miscellaneous Provisions - The system will be effective upon approval by the shareholders' meeting and is subject to interpretation and revision by the board [14]

山东百龙创园生物科技股份有限公司 章 程 2025 年 7 月 目 录 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）和其他有关规定，制订本章程。 第二条 山东百龙创园生物科技股份有限公司（以下简称"公司"）系依照 《公司法》和其他有关规定发起成立的股份有限公司。公司在德州市行政审批服 务局注册登记，取得统一社会信用代码为 9137148278349486XB 的《营业执照》。 第三条 公司于 2021 年 3 月 26 日经中国证券监督管理委员会批准，首次向 社会公众发行人民币普通股 3,180 万股，于 2021 年 4 月 21 日在上海证券交易所 上市。 第五章 董事会 第四条 公司注册名称： 1 中文名称：山东百龙创园生物科技股份有限公司 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 ...

山东百龙创园生物科技股份有限公司 重大信息内部报告制度 山东百龙创园生物科技股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为加强山东百龙创园生物科技股份有限公司（以下简称"公司"） 重大信息内部报告工作的管理，保证公司内部重大信息的快速传递、归集和有效 管理，及时、真实、准确、完整、公平地披露信息，维护投资者的合法权益，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上 市规则》《上市公司信息披露管理办法》等有关法律、法规、规范性文件以及《山 东百龙创园生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 特制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负 有报告义务的有关人员（以下简称"信息报告义务人"）、部门和单位，应当及 时将有关信息通过董事会秘书向公司董事会报告的制度。 第四条 本制度所称"信息报告义务人"包括： （一）公司董事、高级管理人员、各部门（含各分公司、各子公司）的主要 负责人和指定联络人； 第五条 公司董事会负责管理公司重大信息及其披露 ...

山东百龙创园生物科技股份有限公司 山东百龙创园生物科技股份有限公司 股东会议事规则 股东会议事规则 第一章 总则 第一条 为规范山东百龙创园生物科技股份有限公司（以下简称"公司"） 股东会及股东行为，提高股东会议事效率，保障股东的合法权益，确保股东会能 够依法行使职权和依法决议，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等相关法律、行 政法规和规范性文件以及《山东百龙创园生物科技股份有限公司章程》（以下简 称"《公司章程》"）的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》及本规则的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的六个月内举行。临时股东会不定期召开，出现《公 司章程》规定的应当召开临时股东会的情形时，临时股东会应当在二个月内召开。 ...

山东百龙创园生物科技股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 山东百龙创园生物科技股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第一章 总 则 第一条 为加强对山东百龙创园生物科技股份有限公司（以下简称"公司"） 董事和高级管理人员所持本公司股份及其变动的管理，进一步明确办理程序，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司董事和高级管理人员所持本公司股份及其 变动管理规则》《上市公司股东减持股份管理暂行办法》等相关法律法规、规范 性文件以及《山东百龙创园生物科技股份有限公司章程》（以下简称"《公司章程》"） 的规定，并结合本公司具体情况，制定本制度。 第二条 本制度适用于公司董事和高级管理人员及前述人员的一致行动人 所持本公司股份及其变动的管理。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下和利 用他人账户持有的所有本公司股份；公司董事和高级管理人员从事融资融券交易 的，其所持有本公司股份还包括记载在其信用账户内的本公司股份。 公司董事和高级管理人员就限制股份转让做出承诺的 ...

山东百龙创园生物科技股份有限公司 股东会网络投票管理制度 山东百龙创园生物科技股份有限公司 （一）交易系统投票平台； 股东会网络投票管理制度 第一章 总则 第一条 为规范山东百龙创园生物科技股份有限公司（以下简称"公司"）股 东会网络投票行为，保护投资者合法权益，根据《中华人民共和国公司法》《上 市公司股东会规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等相关法律、行政法规、规章、规范性文件和《公司章程》《股东会议事规 则》的有关规定，制定本管理制度。 （二）互联网投票平台（网址：vote.sseinfo.com）。 第三条 公司召开股东会，应当设置会场，以现场会议形式召开，并按照相 关规定向股东提供网络投票方式，履行股东会相关的通知和公告义务，做好股东 会网络投票的相关组织和准备工作。 第四条 公司为股东提供网络投票方式的，应当按照上交所相关临时公告格 式指引的要求，使用上交所公告编制软件编制股东会相关公告，并按规定披露。 第五条 股东会股权登记日登记在册且有权出席会议行使表决权的所有股东， 均可以通过网络投票系统行使表决权，但同一股份只能选择现场投票、网络投票 或符合规定的其他投票方 ...

山东百龙创园生物科技股份有限公司 独立董事工作制度 山东百龙创园生物科技股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善山东百龙创园生物科技股份有限公司（以下简称"公 司"）的治理结构，促进公司规范运作，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》《上市公司独立董事管理办法》《上 海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》《上市公司治理准则》等有关法律、法规、规范性文件及《山东百 龙创园生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，特 制定本制度。 第二章 一般规定 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交 易所业务规则和《公司章程》的规定，认真履 ...